Genmab — August 2018
-
Operating income was DKK 459 million in the first half of 2018 compared to DKK 582 million in the first half of 2017. The decrease of DKK 123 million, or 21%, was driven by increased operating expenses, which was partly offset by higher revenue.
-
Genmab is maintaining its 2018 financial guidance published on February 21, 2018.
-
Tjah...
-
Im sorry EL i forgot im only allowed to come with postive statements. I will rephrase: The financial statement looks fantastic just as
everyone has expected. im sure all the shorters will close their positions now and the stock price will rise to 1300 in the following week on this great news. Forget how the market has reacted to all the other danish c25 companies financial statements and the current market sentiments. -
Det ville have været meget overraskende havde vi fået en opjustering idag. Regnskabet var som forventet, videre i teksten. Jvf seneste tids kursudvikling, har der ikke været forventninger til regnskab, så hvis vi skal ned i morgen er det pga storinvestors fortsatte udsalg, ikke pga regnskabet
-
-
Man må komme med alle de negative kommentarer man vil.
-
Her i chatten er mange tilfredse med det fundamentale. De færreste er tilfredse med kursudviklingen.
-
I tilfældet med dagens regnskab viser det blot at næsen er ned i det spor som selskabet har guidet med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind